share_log

bluebird bio | NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB

bluebird bio | NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB

bluebird bio | NT 10-Q:季報延遲披露公告
美股SEC公告 ·  08/14 07:14

Moomoo AI 已提取核心訊息

bluebird bio, Inc. has filed a notification of late filing with the Securities and Exchange Commission (SEC), indicating that it will not be able to submit its Quarterly Report on Form 10-Q for the period ended June 30, 2024, by the prescribed due date of August 14, 2024. The delay is attributed to the company's ongoing efforts to restate its financial statements for the year ended December 31, 2022, and for the first three quarters of both 2022 and 2023. This restatement process has also affected the timely filing of its Annual Report for 2023 and the First Quarter Report for 2024. bluebird bio is working diligently to complete the restatement and file all outstanding reports as soon as possible. The company anticipates significant changes in its results of operations for the quarter ended June 30, 2024, compared to the same period in 2023, due to identified errors in lease and non-lease component accounting in agreements with contract manufacturing organizations. However, the company has stated that these errors are not expected to impact its cash position or revenue.
bluebird bio, Inc. has filed a notification of late filing with the Securities and Exchange Commission (SEC), indicating that it will not be able to submit its Quarterly Report on Form 10-Q for the period ended June 30, 2024, by the prescribed due date of August 14, 2024. The delay is attributed to the company's ongoing efforts to restate its financial statements for the year ended December 31, 2022, and for the first three quarters of both 2022 and 2023. This restatement process has also affected the timely filing of its Annual Report for 2023 and the First Quarter Report for 2024. bluebird bio is working diligently to complete the restatement and file all outstanding reports as soon as possible. The company anticipates significant changes in its results of operations for the quarter ended June 30, 2024, compared to the same period in 2023, due to identified errors in lease and non-lease component accounting in agreements with contract manufacturing organizations. However, the company has stated that these errors are not expected to impact its cash position or revenue.
bluebird bio已向美國證券交易委員會(SEC)提交了逾期申報通知,表示將無法按規定的截止日期2024年8月14日前提交截至2024年6月30日的10-Q表。這一延期歸因於公司正在努力重述其2022年12月31日和2022年、2023年前三個季度的財務報表。這一重述過程也影響了其2023年年度報告和2024年第一季度報告的及時提交。bluebird bio正在努力完成重述工作,並儘快提交所有未提交的報告。公司預計,由於與合同製造組織協議中租賃和非租賃組成部分的會計錯誤,2024年6月30日季度的經營業績將與2023年同期相比出現顯著變化。然而,該公司已經聲明,這些錯誤不會影響其現金狀況或營業收入。
bluebird bio已向美國證券交易委員會(SEC)提交了逾期申報通知,表示將無法按規定的截止日期2024年8月14日前提交截至2024年6月30日的10-Q表。這一延期歸因於公司正在努力重述其2022年12月31日和2022年、2023年前三個季度的財務報表。這一重述過程也影響了其2023年年度報告和2024年第一季度報告的及時提交。bluebird bio正在努力完成重述工作,並儘快提交所有未提交的報告。公司預計,由於與合同製造組織協議中租賃和非租賃組成部分的會計錯誤,2024年6月30日季度的經營業績將與2023年同期相比出現顯著變化。然而,該公司已經聲明,這些錯誤不會影響其現金狀況或營業收入。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息